Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Proteomic characterization of microdissected breast tissue environment provides a protein-level overview of malignant transformation.

Braakman RB, Stingl C, Tilanus-Linthorst MM, van Deurzen CH, Timmermans MA, Smid M, Foekens JA, Luider TM, Martens JW, Umar A.

Proteomics. 2017 Mar;17(5). doi: 10.1002/pmic.201600213.

2.

Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.

Obdeijn IM, Heijnsdijk EA, Hunink MG, Tilanus-Linthorst MM, de Koning HJ.

Eur J Cancer. 2016 Aug;63:135-42. doi: 10.1016/j.ejca.2016.05.012. Epub 2016 Jun 15.

PMID:
27318001
3.

[Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients].

Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM.

Ned Tijdschr Geneeskd. 2016;160:A9800. Dutch.

PMID:
27122073
4.

Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.

Phi XA, Saadatmand S, De Bock GH, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Hooning MJ, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, Tilanus-Linthorst MM, van den Heuvel ER, Houssami N.

Br J Cancer. 2016 Mar 15;114(6):631-7. doi: 10.1038/bjc.2016.32. Epub 2016 Feb 23.

5.

Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients.

Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM.

BMJ. 2015 Oct 6;351:h4901. doi: 10.1136/bmj.h4901.

6.

Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization.

Zhang B, Shu XO, Delahanty RJ, Zeng C, Michailidou K, Bolla MK, Wang Q, Dennis J, Wen W, Long J, Li C, Dunning AM, Chang-Claude J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Neven P, Wildiers H, Floris G, Schmidt MK, Rookus MA, van den Hurk K, de Kort WL, Couch FJ, Olson JE, Hallberg E, Vachon C, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Li J, Humphreys K, Brand J, Guénel P, Truong T, Cordina-Duverger E, Menegaux F, Burwinkel B, Marme F, Yang R, Surowy H, Benitez J, Zamora MP, Perez JI, Cox A, Cross SS, Reed MW, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Chenevix-Trench G; kConFab Investigators, Australian Ovarian Study Group, Haiman CA, Henderson BE, Schumacher F, Marchand LL, Lindblom A, Margolin S, Hooning MJ, Martens JW, Tilanus-Linthorst MM, Collée JM, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Giles GG, Milne RL, McLean C, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow AJ, Ashworth A, Orr N, Jones M, Figueroa J, Garcia-Closas M, Brinton L, Lissowska J, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Brüning T, Ko YD, Peterlongo P, Manoukian S, Bonanni B, Radice P, Bogdanova N, Antonenkova N, Dörk T, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubiński J, Jaworska-Bieniek K, Durda K, Hamann U, Torres D, Schmutzler RK, Neuhausen SL, Anton-Culver H, Kristensen VN, Grenaker Alnæs GI; DRIVE Project, Pierce BL, Kraft P, Peters U, Lindstrom S, Seminara D, Burgess S, Ahsan H, Whittemore AS, John EM, Gammon MD, Malone KE, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Pharoah PD, Simard J, Hall P, Hunter DJ, Easton DF, Zheng W.

J Natl Cancer Inst. 2015 Aug 20;107(11). pii: djv219. doi: 10.1093/jnci/djv219. Print 2015 Nov.

7.

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.

Lei J, Rudolph A, Moysich KB, Rafiq S, Behrens S, Goode EL, Pharoah PP, Seibold P, Fasching PA, Andrulis IL, Kristensen VN, Couch FJ, Hamann U, Hooning MJ, Nevanlinna H, Eilber U, Bolla MK, Dennis J, Wang Q, Lindblom A, Mannermaa A, Lambrechts D, García-Closas M, Hall P, Chenevix-Trench G, Shah M, Luben R, Haeberle L, Ekici AB, Beckmann MW, Knight JA, Glendon G, Tchatchou S, Alnæs GI, Borresen-Dale AL, Nord S, Olson JE, Hallberg E, Vachon C, Torres D, Ulmer HU, Rüdiger T, Jager A, van Deurzen CH, Tilanus-Linthorst MM, Muranen TA, Aittomäki K, Blomqvist C, Margolin S, Kosma VM, Hartikainen JM, Kataja V, Hatse S, Wildiers H, Smeets A, Figueroa J, Chanock SJ, Lissowska J, Li J, Humphreys K, Phillips KA; kConFab Investigators, Linn S, Cornelissen S, van den Broek SA, Kang D, Choi JY, Park SK, Yoo KY, Hsiung CN, Wu PE, Hou MF, Shen CY, Teo SH, Taib NA, Yip CH, Ho GF, Matsuo K, Ito H, Iwata H, Tajima K, Dunning AM, Benitez J, Czene K, Sucheston LE, Maishman T, Tapper WJ, Eccles D, Easton DF, Schmidt MK, Chang-Claude J.

Breast Cancer Res. 2015 Feb 10;17:18. doi: 10.1186/s13058-015-0522-2.

8.

Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).

Saadatmand S, Obdeijn IM, Rutgers EJ, Oosterwijk JC, Tollenaar RA, Woldringh GH, Bergers E, Verhoef C, Heijnsdijk EA, Hooning MJ, de Koning HJ, Tilanus-Linthorst MM.

Int J Cancer. 2015 Oct 1;137(7):1729-38. doi: 10.1002/ijc.29534. Epub 2015 Apr 17.

9.

Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.

Phi XA, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Tilanus-Linthorst MM, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, de Koning HJ, Van den Heuvel ER, de Bock GH.

J Clin Oncol. 2015 Feb 1;33(4):349-56. doi: 10.1200/JCO.2014.56.6232. Epub 2014 Dec 22.

PMID:
25534390
10.

Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.

Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON).

Int J Cancer. 2014 Dec 15;135(12):2940-9. doi: 10.1002/ijc.28941. Epub 2014 May 20.

11.

Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.

Obdeijn IM, Winter-Warnars GA, Mann RM, Hooning MJ, Hunink MG, Tilanus-Linthorst MM.

Breast Cancer Res Treat. 2014 Apr;144(3):577-82. doi: 10.1007/s10549-014-2888-8. Epub 2014 Feb 25.

PMID:
24567197
12.

Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.

van Verschuer VM, Heemskerk-Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus-Linthorst MM, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C.

Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14.

13.

Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Ellis S, Frost D, Platte R, Perkins J, Evans DG, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Scuvera G, Manoukian S, Bonanni B, Mariette F, Fortuzzi S, Viel A, Pasini B, Papi L, Varesco L, Balleine R, Nathanson KL, Domchek SM, Offitt K, Jakubowska A, Lindor N, Thomassen M, Jensen UB, Rantala J, Borg Å, Andrulis IL, Miron A, Hansen TV, Caldes T, Neuhausen SL, Toland AE, Nevanlinna H, Montagna M, Garber J, Godwin AK, Osorio A, Factor RE, Terry MB, Rebbeck TR, Karlan BY, Southey M, Rashid MU, Tung N, Pharoah PD, Blows FM, Dunning AM, Provenzano E, Hall P, Czene K, Schmidt MK, Broeks A, Cornelissen S, Verhoef S, Fasching PA, Beckmann MW, Ekici AB, Slamon DJ, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Aittomäki K, Muranen TA, Heikkilä P, Blomqvist C, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Olson JE, Pankratz VS, John EM, Whittemore AS, West DW, Hamann U, Torres D, Ulmer HU, Rüdiger T, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, Eccles DM, Tapper WJ, Durcan L, Jones L, Peto J, dos-Santos-Silva I, Fletcher O, Johnson N, Dwek M, Swann R, Bane AL, Glendon G, Mulligan AM, Giles GG, Milne RL, Baglietto L, McLean C, Carpenter J, Clarke C, Scott R, Brauch H, Brüning T, Ko YD, Cox A, Cross SS, Reed MW, Lubinski J, Jaworska-Bieniek K, Durda K, Gronwald J, Dörk T, Bogdanova N, Park-Simon TW, Hillemanns P, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Burwinkel B, Marme F, Surovy H, Yang R, Anton-Culver H, Ziogas A, Hooning MJ, Collée JM, Martens JW, Tilanus-Linthorst MM, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Lindblom A, Margolin S, Joseph V, Robson M, Rau-Murthy R, González-Neira A, Arias JI, Zamora P, Benítez J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Peterlongo P, Zaffaroni D, Barile M, Capra F, Radice P, Teo SH, Easton DF, Antoniou AC, Chenevix-Trench G, Goldgar DE; ABCTB Investigators; EMBRACE Group; GENICA Network; HEBON Group; kConFab Investigators.

Breast Cancer Res. 2014 Dec 23;16(6):3419. doi: 10.1186/s13058-014-0474-y.

14.

Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.

Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2013 Sep 4;105(17):1314-21. doi: 10.1093/jnci/djt203. Epub 2013 Aug 12.

PMID:
23940285
15.

Breast fine-needle aspiration cytology performance in the high-risk screening population: a study of BRCA1/BRCA2 mutation carriers.

Georgieva RD, Obdeijn IM, Jager A, Hooning MJ, Tilanus-Linthorst MM, van Deurzen CH.

Cancer Cytopathol. 2013 Oct;121(10):561-7. doi: 10.1002/cncy.21308. Epub 2013 May 29.

16.

Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.

Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collée JM, Seynaeve C, Hooning MJ.

Ann Oncol. 2013 Aug;24(8):2029-35. doi: 10.1093/annonc/mdt134. Epub 2013 Apr 10.

PMID:
23576707
17.

Preoperative breast MRI can reduce the rate of tumor-positive resection margins and reoperations in patients undergoing breast-conserving surgery.

Obdeijn IM, Tilanus-Linthorst MM, Spronk S, van Deurzen CH, de Monye C, Hunink MG, Menke MB.

AJR Am J Roentgenol. 2013 Feb;200(2):304-10. doi: 10.2214/AJR.12.9185.

PMID:
23345350
18.

Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk.

Tilanus-Linthorst MM, Lingsma HF, Evans DG, Thompson D, Kaas R, Manders P, van Asperen CJ, Adank M, Hooning MJ, Kwan Lim GE, Eeles R, Oosterwijk JC, Leach MO, Steyerberg EW.

Int J Cancer. 2013 Jul;133(1):156-63. doi: 10.1002/ijc.28014. Epub 2013 Feb 13.

19.

Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.

Saadatmand S, Rutgers EJ, Tollenaar RA, Zonderland HM, Ausems MG, Keymeulen KB, Schlooz-Vries MS, Koppert LB, Heijnsdijk EA, Seynaeve C, Verhoef C, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MM.

BMC Cancer. 2012 Oct 2;12:440. doi: 10.1186/1471-2407-12-440.

20.

9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium.

Warren H, Dudbridge F, Fletcher O, Orr N, Johnson N, Hopper JL, Apicella C, Southey MC, Mahmoodi M, Schmidt MK, Broeks A, Cornelissen S, Braaf LM, Muir KR, Lophatananon A, Chaiwerawattana A, Wiangnon S, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, Sawyer EJ, Tomlinson I, Kerin M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Laurent-Puig P, Mulot C, Bojesen SE, Nielsen SF, Flyger H, Nordestgaard BG, Milne RL, Benítez J, Arias-Pérez JI, Zamora MP, Anton-Culver H, Ziogas A, Bernstein L, Dur CC, Brenner H, Müller H, Arndt V, Langheinz A, Meindl A, Golatta M, Bartram CR, Schmutzler RK, Brauch H, Justenhoven C, Brüning T; GENICA Network, Chang-Claude J, Wang-Gohrke S, Eilber U, Dörk T, Schürmann P, Bremer M, Hillemanns P, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova N, Antonenkova N, Rogov Y, Bermisheva M, Prokofyeva D, Zinnatullina G, Khusnutdinova E, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Hartikainen JM, Kataja V, Chenevix-Trench G, Beesley J, Chen X; kConFab Investigators; Australian Ovarian Cancer Study Group, Lambrechts D, Smeets A, Paridaens R, Weltens C, Flesch-Janys D, Buck K, Behrens S, Peterlongo P, Bernard L, Manoukian S, Radice P, Couch FJ, Vachon C, Wang X, Olson J, Giles G, Baglietto L, McLean CA, Severi G, John EM, Miron A, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Mulligan AM, Weerasooriya N, Devilee P, Tollenaar RA, Martens JW, Seynaeve CM, Hooning MJ, Hollestelle A, Jager A, Tilanus-Linthorst MM, Hall P, Czene K, Liu J, Li J, Cox A, Cross SS, Brock IW, Reed MW, Pharoah P, Blows FM, Dunning AM, Ghoussaini M, Ashworth A, Swerdlow A, Jones M, Schoemaker M, Easton DF, Humphreys M, Wang Q, Peto J, dos-Santos-Silva I.

Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1783-91. doi: 10.1158/1055-9965.EPI-12-0526. Epub 2012 Aug 2.

Supplemental Content

Loading ...
Support Center